Detection of drug resistant mycobacterium tuberculosis strains using Kit SIRE Nitratase® : a multicenter study.

• Autor(a) principal: Miranda, Silvana Spindola de
• Data de Publicação: 2020
• Outros Autores: Almeida, Isabela Neves de, Mansur, Maria de Fátima Filardi Oliveira, Figueredo, Lida Jouca de Assis, Carvalho, Wânia da Silva, Hadaad, João Paulo Amaral, Diniz, Jaciara de Lourdes do Carmo Guimarães, Groll, Andrea von, Silva, Pedro Almeida da, Lopes, Maria Luiza, Santos, Marcelo Cordeiro dos, Brito, Alexandra, Mello, Fernanda Carvalho de Queiroz, Malaquias, Thiago da Silva Santos, Croda, Julio, Pinhata, Juliana Maira Watanabe, Oliveira, Rosângela Siqueira de, Chimara, Erica, Rossetti, Maria Lúcia, Halon, Maria Laura, Lourenço, Maria Cristina, Medeiros, Reginalda Ferreira de Melo, Montes, Fátima Cristina Onofre Fandinho, Machado, Diana, Viveiros, Miguel, Kritski, Afrânio Lineu
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFOP
• Texto Completo: http://www.repositorio.ufop.br/jspui/handle/123456789/15951; https://doi.org/10.1590/1678-4324-2020190179
• topic: Multidrug resistant tuberculosis; Nitrate reductase; Technology

(1) Background: The Commercial Kit SIRE Nitratase® PlastLabor, is a drug susceptibility test kit used to detect Mycobacterium tuberculosis resistance to first-line TB treatment drugs. The present study aimed at evaluating its performance in a multicenter study. (2) Methods: To determine its accuracy, the proportion methods in Lowenstein Jensen medium or the BACTECTMMGITTM960 system was used as a gold standard. (3) Results: The study revealed that the respective accuracies of the kit with 190 M. tuberculosis clinical isolates, using the proportion methods in Lowenstein Jensen medium or BACTECTMMGITTM960 system as a gold standard, were 93.9% and 94.6%, 96.9% and 94.6%, 98.0% and 97.8%, and 98.0% and 98.9%, for streptomycin, isoniazid, rifampicin, and ethambutol, respectively. (4) Conclusion: Thus, the kit can rapidly screen resistance to streptomycin, isoniazid, rifampicin, and ethambutol. Additionally, it does not require sophisticated equipment; hence, it can be easily used in the laboratories of low and middle income countries.